RVX 208
RDI PROFILE - europepmc.org
RDI PROFILE
europepmc.orgAbstract RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in
development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and
Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein
cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review
discusses the key development milestones and therapeutic trials of this drug.
development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and
Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein
cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review
discusses the key development milestones and therapeutic trials of this drug.
Abstract RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therapeutic trials of this drug.
europepmc.org